BMY241227P47000
- 0.19
- 0.000.00%
Bristol-Myers Squibb Newsroom
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.
Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Express News | Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile
Express News | Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
Express News | Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Express News | Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
J.P. Morgan Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Raises Target Price to $70
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
Express News | Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
Express News | Fangzhou Inc and Bristol-Myers Squibb have joined forces in China to establish a strategic alliance to jointly promote Digital Health.
Unusual Options Activity: NVT, IDXX and Others Attract Market Bets, NVT V/OI Ratio Reaches 238.0
EST Dec 18th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Insitro Receives $25M In Milestone Payments From Bristol Myers Squibb For Achievement Of Discovery Milestones And Selection Of First Novel Genetic Target For ALS
Insitro Receives $25 Million in Milestone Payments From Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS